Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 18, 2025 -- For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published online June 11 in The Lancet Psychiatry.
Leslie Citrome, M.D., from the New York Medical College School of Medicine in Valhalla, and colleagues conducted an open-label, nonrandomized, phase 3 trial involving clinically stable participants with schizophrenia or schizoaffective disorder. Participants received five doses of long-acting oral weekly LYN-005 (15 mg or 45 mg), with a supplemental half dose of daily immediate-release risperidone during week 1, after a seven-day run-in period with immediate-release risperidone. Pharmacokinetic parameters of LYN-005 (minimum concentration [Cmin] at weeks 1 and 5, and maximum concentration [Cmax] and average concentration [Cavg] at week 5) were compared to those of immediate-release risperidone on the last day of the run-in period.
Eighty-three patients were enrolled in the study, 47 of whom completed the study. The researchers found that sustained release of the active moiety was observed across all doses of LYN-005 in the pharmacokinetic analysis. The geometric mean ratios of LYN-005 versus immediate-release risperidone met the predetermined criteria and were 1.02 for Cmin at week 1 and 1.04, 0.84, and 1.03 for Cmin, Cmax, and Cavg, respectively, at week 5. Gastrointestinal treatment-emergent adverse events were most common among individuals taking LYN-005 (66 percent); there was one serious treatment-emergent adverse event.
"Having the option to take medication by mouth once a week represents an important option that can assist with adherence for the many patients who would prefer oral medications versus injectable formulations," Citrome said in a statement.
Several authors disclosed ties to biopharmaceutical companies, including Lyndra Pharmaceuticals, which is developing LYN-005 and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
One in 10 Mental Health-Related ED Visits Among Youths Involve Boarding
WEDNESDAY, Aug. 20, 2025 -- Boarding is a considerable issue for Medicaid-enrolled youths seeking mental health care in emergency departments (EDs), according to a research letter...
Mental Health Hospitalizations Common in Adults With Autism
WEDNESDAY, July 23, 2025 -- Mental health hospitalizations are more common among adults with autism, with more than one-third of all admissions tied to mental health conditions...
Chronic Exposure to Systemic Inflammation May Increase Risk for Affective Disorders
THURSDAY, July 3, 2025 -- For individuals with specific autoimmune conditions, there appears to be an increased risk for affective disorders, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.